NCT05265052 2026-03-11
3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain
3D Medicines
Phase 2 Not yet recruiting
Clinical Trials
14 trialsNCT04808531 2022-04-12
NanaBisâ„¢ an Oro-buccal Administered delta9-Tetrahydrocannabinol (d9-THC) & Cannabidiol (CBD) Medicine for the Management of Bone Pain From Metastatic Cancers
Medlab Clinical
Phase 3 Unknown
NCT03564548 2021-07-28
REBORN
Tetra Bio-Pharma
Phase 2 Unknown
NCT03176121 2020-03-18
STOP Pain
Taiwan Mundipharma Pharmaceuticals Ltd.
Phase 4 Completed
NCT03176199 2020-03-18
A Study to Compare the Titration Efficacy and Safety of Control-released Oxycodone and Immediate-released Oxycodone in Patients With Moderate to Severe Cancer Pain
Taiwan Mundipharma Pharmaceuticals Ltd.
Phase 4 Completed
NCT01885182 2019-10-04
Determine the Safety and Efficacy of Oxy/Nal Tablets Compared to Oxy PR in Subjects With Cancer Pain
Mundipharma (China) Pharmaceutical Co. Ltd
Phase 3 Completed
NCT02660229 2018-11-19
SWITCH
Mundipharma Korea Ltd
Phase 4 Completed
NCT00513656 2018-10-23
A Study Comparing Oxycodone to Oxycodone/Naloxone in Moderate to Severe, Chronic Cancer Pain
Mundipharma Research GmbH & Co KG
Phase 2 Completed
NCT01675622 2018-05-21
Immediate-Release Oxycodone Capsules Study in Cancer Pain
Mundipharma (China) Pharmaceutical Co. Ltd
Phase 3 Completed
NCT01313780 2017-12-22
TOP
Mundipharma Korea Ltd
Phase 4 Completed
NCT01918098 2017-11-14
Targin for Non-cancer Pain
Mundipharma (China) Pharmaceutical Co. Ltd
Phase 3 Completed
NCT01675531 2016-12-16
A Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN)
Mundipharma Korea Ltd
Phase 4 Completed
NCT02321397 2016-11-04
To Demonstrate Equivalence in Analgesic Efficacy & Bowel Function Between OXN PR Higher Dose & Lower Dose Tablet Strengths in Subjects With Non-cancer or Cancer Pain
Mundipharma Research GmbH & Co KG
Phase 2/3 Completed
NCT00822614 2009-01-14
FINDS
Akela Pharma, Inc.
Phase 3 Unknown